Top Industry Leaders in the Autism Disorder and Treatment Market
*Disclaimer: List of key companies in no particular orderLatest Autism Disorder and treatment Companies Update
-
Sep 2023: Merck announced that the American health agency will prioritize reviewing its experimental medication for a specific type of degenerative blood vessel dysfunction. Through its $11.5 billion acquisition of Acceleron Pharma in 2021, the pharmaceutical company acquired the rights to the sotatercept medication. The target action date for the review has been recognized by the US Food and Drug Administration as March 26, 2024, according to Merck. If authorized, the treatment will assist the American pharmaceutical company diversify its revenue stream as Keytruda, a popular cancer immunotherapy, approaches the loss of its market exclusivity in 2028. According to findings from a late-stage investigation, sotatercept paired with a background medication allowed patients with pulmonary arterial hypertension (PAH) to walk roughly 40.8 meters further in just one hour.
-
Oct 2023: GSK Plc and Pfizer Inc. are on track to sell $2 billion of their new RSV vaccines for older individuals this year, exceeding analysts' expectations by more than five times. According to research by BI analyst John Murphy, the injections are in higher demand than anticipated based on preliminary data from US prescription sales for GSK's Arexvy and Pfizer's Abrysvo. If that rate is maintained, up to 6.5 million individuals in the US could receive injections this year alone.
List of Autism Disorder and treatment Key companies in the market
- Pfizer Inc.
- Eli Lilly and Company
- Allergan
- Merck & CO Inc.
- Teva Pharmaceutical Industries Ltd.
- Concern Pharma Private Limited
- Novartis AG
- Johnson & Johnson ServicesInc.
- Bristol-Myers Squibb
- Otsuka Holdings Co.